Home > Resources > Company Profiles > Genentech Inc

Genentech Inc (DNA)

Your Name

Your Email Address *
Send a copy to me

Recipient's Email Address *

Separate multiple email addresses (max 20) with commas.

Subject *

Message

0/1500

Email Confirmation

Dr.Arthur D. Levinson, Ph.D. , CEO/Chairman of the Board/Director

www.gene.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

A biotechnology company which discovers, develops and manufactures pharmaceutical products to treat patients with medical needs.

Portfolio Articles

Putting a Price on Innovation
While Genentech weighs Roche's offer, the future of Big Biotech is at stake.

Jul 25 2008
Buying the Pharma Team
Offer for Genentech is part of a wave.
Jul 21 2008
Genes 'R' Us: The New Dot-Coms?
DNA tests for everything from diseases to ancestry are proliferating as a nascent industry tries to spark a revolution. Is this déjà vu all over again?
Mar 05 2008
Welcome to the Future
With a little help from Google, secretive Silicon Calley startup 23andMe is betting you’ll want to web-surf your own DNA. But is the science ready?

Oct 15 2007

See more news on this company

News Feeds

Final Glance: Biotechnology companies AP
Nov 21 2008
Midday Glance: Biotechnology companies AP
Nov 21 2008
Early Glance: Biotechnology companies AP
Nov 21 2008
US-BUSINESS Summary Reuters
Nov 09 2008
Roche sticks by $43.7 billion Genentech bid: report Reuters
Nov 09 2008
OSI shares jump on lung cancer study data AP
Nov 07 2008
Tarceva meets goal in first-line lung cancer trial AP
Nov 07 2008
Genentech seeks Avastin approval in brain cancer AP
Nov 03 2008
Biogen, Genentech to codevelop cancer drug AP
Oct 30 2008
Biotech stocks rise with the market on rate cut AP
Oct 29 2008

Portfolio Blogs

The Trouble With Tickers
Aug 11 2008

Press Releases

Genentech Issues Dear Healthcare Provider Letter Regarding a 2nd Case of PML in a Raptiva Patient Nov-17-2008, 05:30PM EST
Curis to Present at Lazard Capital Markets 5th Annual Healthcare Conference Nov-13-2008, 04:05PM EST
Curis Announces Collaborator Genentech's License of Ex-U.S. Rights to GDC-0449 to Roche Nov-13-2008, 08:00AM EST
CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate Nov-13-2008, 08:00AM EST
Insmed Gains Royalty-Free Worldwide Rights for IPLEX(TM) in Connection with Potential Expanded Access ALS Programs Nov-10-2008, 08:00AM EST

News From Around the Web

News

Verizon fires 14, alleges false reporting of hours (Boston Globe)

Nov 23 2008
Genentech Adds Onto Thursday's Steep Loss (RTTNews)

Nov 22 2008
Final Glance: Biotechnology companies (Boston Globe)

Nov 21 2008
Early Glance: Biotechnology companies (MSN Money)

Nov 21 2008
Biotechnology companies shares down at the close of trading (Canadian Business Online)

Nov 19 2008
Biotechnology companies shares mixed at 10 a.m. (Canadian Business Online)

Nov 19 2008
Biotechnology companies shares mixed at noon (Canadian Business Online)

Nov 18 2008
FDA Contradicts Genentech on Eye Drug (Wall Street Journal Health Blog)

Nov 18 2008

Blogs

AstraZeneca Provides Zest and Zeal For OSI Pharmaceuticals (CNBC: Pharmas Market with Mike Huckman)

Nov 19 2008
Genentech Disputes Avastin And Blood Clot Risk (Pharmalot)

Nov 19 2008

Employees

Number of Employees: 11,174

Revenue per Employee: $1,113,073

Top Executives

David A. Ebersman, Executive VP/CFO

Patrick Y. Yang, Ph.D., Divisional Executive VP

Richard H. Scheller, Ph.D., Divisional Executive VP

Dr. Hal Barron, M.D., F.A.C.C., Chief Medical Officer/Senior VP, Divisional

Robert L. Garnick, Ph.D., Divisional Senior VP

Ian T. Clark, Divisional Executive VP

Robert E. Andreatta, Chief Accounting Officer/Controller

Dr.Susan D. Desmond-Hellmann, M.D., M.P.H., Divisional President

John M. Whiting, Vice President, Divisional

Stephen G. Juelsgaard, D.V.M., J.D., Executive VP/Other Executive Officer/Secretary

Board of Directors

Dr. Jonathan K.C. Knowles, Ph.D., Director

Debra L. Reed, Director

Dr.Herbert W. Boyer, Ph.D., Director/Founder

Dr. Erich Hunziker, Ph.D., Director

Stephen G. Juelsgaard, D.V.M., J.D., Executive VP/Other Executive Officer/Secretary

William Matt Burns, Director

Dr.Charles A. Sanders, M.D., Director

Financials

Quarterly

Annual

Income Statement	10/2008	07/2008	04/2008	01/2008
Sales	724 Mil.	441 Mil.	389 Mil.	344 Mil.
Gross Operating Profit	2.69 Bil.	2.8 Bil.	2.67 Bil.	2.63 Bil.
Operating Income before D & A (EBITDA)	1.3 Bil.	1.27 Bil.	1.54 Bil.	1.04 Bil.
Total Income Before Interest Expenses (EBIT)	1.22 Bil.	1.32 Bil.	1.28 Bil.	1.02 Bil.
Total Net Income	731 Mil.	782 Mil.	790 Mil.	632 Mil.
Basic EPS, Total	0.69	0.74	0.75	0.6
Diluted EPS, Total	0.68	0.73	0.74	0.59

BALANCE STATEMENT	10/2008	07/2008	04/2008	01/2008
Cash and Equivalents	5.93 Bil.	4.5 Bil.	4.86 Bil.	NA
Total Assets	NA	NA	NA	NA
Total Liabilities	2.84 Bil.	2.7 Bil.	3.97 Bil.	NA
Total Capitalization	17.13 Bil.	15.76 Bil.	15.37 Bil.	NA

Cash Flow	10/2008	07/2008	04/2008	01/2008
Net Cash From Continuing Operations	NA	NA	NA	NA
Net Cash From Investing Activities	NA	NA	NA	NA
Net Cash From Financing Activities	NA	NA	NA	NA
Net Change in Cash & Cash Equivalents	NA	NA	NA	NA

Income Statement	2008	2007	2006	2005
Sales	1.57 Bil.	774 Mil.	640.9 Mil.	319.3 Mil.
Gross Operating Profit	10.15 Bil.	8.51 Bil.	5.99 Bil.	3.66 Bil.
Operating Income before D & A (EBITDA)	4.37 Bil.	4.72 Bil.	2.47 Bil.	1.03 Bil.
Total Income Before Interest Expenses (EBIT)	4.5 Bil.	3.48 Bil.	2.06 Bil.	1.23 Bil.
Total Net Income	2.77 Bil.	2.11 Bil.	1.28 Bil.	784.82 Mil.
Basic EPS, Total	2.63	2.01	1.21	0.74
Diluted EPS, Total	2.59	1.97	1.18	0.73

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	NA	1.25 Bil.	1.23 Bil.	270.12 Mil.
Total Assets	NA	5.7 Bil.	4.42 Bil.	3.42 Bil.
Total Liabilities	NA	2.16 Bil.	1.66 Bil.	1.24 Bil.
Total Capitalization	NA	11.68 Bil.	9.55 Bil.	7.19 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	NA	2.14 Bil.	2.36 Bil.	1.2 Bil.
Net Cash From Investing Activities	NA	-1.68 Bil.	-1.78 Bil.	-451.56 Mil.
Net Cash From Financing Activities	NA	-432 Mil.	367.53 Mil.	-846.31 Mil.
Net Change in Cash & Cash Equivalents	NA	25 Mil.	955.39 Mil.	-102.03 Mil.

Genentech Inc (DNA)

Company Information

Overview

Employees

Top Executives

Board of Directors

Financials

Company Profile Change Request